Frog and Grateful,
Frog - your estimation of the basis and formula for Dutton's target pps seems quite reasonable if not right on for the info provided at that time. Whether the formula (33% of current pps) would hold true is an interesting exercise if we consider the "what if" the Moffitt partnership was included in the report as well.
Even without the Moffitt news, I believe as Grateful does that the .06 is conservative. I guess that's were Dutton's "speculative buy" comes in...(and of course they are way much more talented and experienced analysts than I am with my humble opinion and limited research!)...
The inclusion of more detail on a major partnership (and with a little more DD connecting the DNAP/Moffitt dots to the big time players like IBM, Affymetrix, Roache Pharmaceutical), would surely have pushed the target pps even higher. JMHO of course, but a partnership (and connections) like this is something that is very high on my investment criteria and strategies for any company I want to invest in.
Grateful - no further news re: Ovanome, just speculating here based on my playful interpretation of the product pipeline chart (the arrows are well into the "trials" column...lol), plus add that we have been working with Moffitt for over 1 1/2 years now and that it's been stated that the clinical trials will only take 6 to 9 months to complete. Other than the start date, I too have not seen formal confirmation as yet.
There was hints about NYU immunosuppression and the NIJ grant for Retinome, but the FAMRI grant was also not include. For potential new investors, every little bit helps build their confidence...
Maybe the researchers should be directed to PatiencePays DNAP Investor site for the latest DNAP news before their next report...lol!
Take care,
Robert
News 
Market Data 
Discover 
